Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its d... Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. 詳細を表示
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024...
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.71 | -21.3213213213 | 3.33 | 3.44 | 2.52 | 392628 | 3.02820142 | CS |
4 | -0.71 | -21.3213213213 | 3.33 | 3.44 | 2.52 | 580816 | 3.04240849 | CS |
12 | -3.89 | -59.7542242704 | 6.51 | 6.645 | 2.52 | 1243973 | 4.27786642 | CS |
26 | -2.26 | -46.3114754098 | 4.88 | 6.75 | 2.52 | 921972 | 4.63428854 | CS |
52 | 0.48 | 22.4299065421 | 2.14 | 7.66 | 2.12 | 757863 | 4.60219636 | CS |
156 | -4.92 | -65.2519893899 | 7.54 | 7.66 | 1.18 | 774649 | 4.8451734 | CS |
260 | -30.38 | -92.0606060606 | 33 | 46.25 | 1.18 | 609034 | 8.5960951 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約